Amgen Tops Q4 Forecasts on Strong Sales and Tax Windfall, Sets Bullish 2026 Outlook
Biotech giant Amgen surpassed Wall Street's fourth-quarter expectations, fueled by robust drug sales volume and a significant tax benefit. The company also issued an optimistic revenue and earnings forecast for 2026, highlighting growth in key products like Repatha and progress in its obesity drug pipeline.